State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

State Street Corp lowered its stake in PDS Biotechnology Co. (NASDAQ:PDSB) by 14.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 111,833 shares of the company’s stock after selling 18,700 shares during the quarter. State Street Corp owned 0.30% of PDS Biotechnology worth $427,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Ground Swell Capital LLC purchased a new stake in PDS Biotechnology during the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PDS Biotechnology during the second quarter worth about $115,000. Vontobel Holding Ltd. grew its stake in shares of PDS Biotechnology by 233.3% in the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after purchasing an additional 28,000 shares during the last quarter. Squarepoint Ops LLC bought a new position in PDS Biotechnology during the 2nd quarter valued at approximately $120,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in PDS Biotechnology in the 2nd quarter worth approximately $146,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Price Performance

PDSB opened at $1.80 on Friday. PDS Biotechnology Co. has a 12-month low of $1.53 and a 12-month high of $6.68. The company has a market cap of $67.34 million, a price-to-earnings ratio of -1.55 and a beta of 1.85. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a fifty day simple moving average of $2.30 and a two-hundred day simple moving average of $2.95.

Wall Street Analyst Weigh In

PDSB has been the subject of a number of recent analyst reports. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a report on Wednesday, December 18th. Finally, B. Riley reduced their price target on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.